Upstream Bio (NASDAQ:UPB) Trading Down 7.3% – Here’s Why

Upstream Bio, Inc. (NASDAQ:UPB)’s share price fell 7.3% during trading on Tuesday . The stock traded as low as $9.30 and last traded at $9.15. 7,240 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 325,232 shares. The stock had previously closed at $9.87.

Upstream Bio Price Performance

The business has a 50-day moving average price of $9.62.

Hedge Funds Weigh In On Upstream Bio

A number of large investors have recently bought and sold shares of UPB. Moody Aldrich Partners LLC purchased a new stake in shares of Upstream Bio during the 4th quarter valued at $1,229,000. Rhumbline Advisers purchased a new stake in Upstream Bio during the fourth quarter valued at about $275,000. Bank of New York Mellon Corp acquired a new stake in Upstream Bio during the fourth quarter worth about $607,000. US Bancorp DE purchased a new position in shares of Upstream Bio in the 4th quarter worth about $27,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Upstream Bio in the 4th quarter valued at about $2,225,000.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.